SYSTEMIC SCLERODERMA TREATMENT MARKET ANALYSIS

Systemic Scleroderma Treatment Market, By Drug Class (Immunosuppressant, Phosphodiesterase 5 inhibitors - PHA, Endothelin Receptor Antagonists, Calcium Channel Blockers, Prostacyclin Analogues, and Others), By Type (Limited Systemic Sclerosis, Diffused Systemic Sclerosis, and Sine Sclerosis), By Route of Administration (Oral, Parenteral, and Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

On March 20, 2024, Cabaletta Bio, Inc., a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to CABA-201. This investigational therapy is a fully human CD19-CAR T cell treatment containing a 4-1BB co-stimulatory domain, aimed at addressing systemic sclerosis (SSc). CABA-201 is being developed as a potential therapy for autoimmune diseases driven by B cells.
On February 19, 2024, Certa Therapeutics, a biotechnology company, announced that the U.S. Food and Drug Administration (FDA) granted fast track designation for its investigational therapy FT011, aimed at treating systemic sclerosis (scleroderma). This follows the earlier Orphan Drug designation granted to FT011.
On January 29, 2024, The Assistance Fund, an independent charitable patient assistance organization that helps patients and families facing high medical out-of-pocket costs, announced the launch of a new financial assistance program for people living with systemic sclerosis. The program is designed to help eligible individuals pay for their out-of-pocket medical costs for treatment such as copayments, health insurance premiums, and incidental medical expenses related to the condition.